Table 3.
Epidemiologic studies of the association between statin use and incident lung cancer risk.
| Author, year | Design* | Number of cases | Results (point estimate (95% CI))** | |
|---|---|---|---|---|
| User | Non-User | |||
| Blais, 2000[35] | CC | 70 | OR=0.94 (0.43–2.05) | |
| Graaf, 2004[45] | CC | 449 | OR=0.89 (0.56–1.42) | |
| Kaye, 2004[49] | CC | 43 | Current use: RR=0.9 (0.6–1.3) | |
| Friis, 2005[46] | Cohort | 73 | 3326 | RR=0.92 (0.72–1.16) Use ≥10 years: RR=0.80 (0.36–1.79) |
| Setoguchi, 2007[44] | Cohort | 179 | 37 | Ever use: HR=1.11 (0.77–1.60) Duration Use <3 years: HR=1.18 (0.72–1.92) Use ≥3 years: HR=1.02 (0.59–1.74) |
| Coogan and Rosenberg, 2007[47] | CC | 31 cases and controls | 424 cases and controls | Regular use: OR=0.7 (0.4–1.1) Duration Use ≤1 year: OR=0.3 (0.1–1.1) Use 1–5 year: OR=0.8 (0.4–1.5) Use ≥5 years: OR=0.9 (0.4–2.1) P for trend in duration: 0.8 |
| Khurana, 2007[78] | CC | 1994 | 161,668 | Ever use: OR=0.55 (0.52–0.59) Use >6 month: OR=0.45 (0.42–0.48) Duration Use 0–6 months: OR=2.32 (2.05–2.63) Use 6–12 months: OR=0.75 (0.63–0.89) Use 1–2 years: OR=0.70 (0.61–0.79) Use 2–4 years: OR=0.49 (0.44–0.55) Use >4 years: OR=0.23 (0.20–0.26) No trend test for duration use |
| Farwell, 2008[66] | Cohort | 436 | 431 | Ever use: HR=0.70 (0.60–0.81) Dose Use ≤10mg: HR=0.70 (0.58–0.84) Use 11–39mg: HR=0.70 (0.57–0.86) Use ≥40mg: HR=0.73 (0.54–0.97) P for trend in dose: 0.002 |
| Friedman, 2007[52] | Cohort | Men: 614 Women: 482 |
Did not report Did not report |
Men Ever use: HR=1.02 (0.94–1.11) Use >5 years: HR=0.82 (0.68–0.99) Women Ever use: HR=1.16 (1.06–1.28) Use >5 years: HR=0.88 (0.70–1.10) |
| Haukka, 2010[50] | Cohort | - | - | RR=0.81 (0.77–0.86) |
*
CC=case control
**
OR=odds ratio; RR=relative risk; HR=hazard ratio; CI=confidence interval; relative to non-users of statin